Data from seven recent influenza seasons in Canada showed the influenza vaccine may be more effective in females than males, according to study findings published in Open Forum Infectious Diseases.
Between 2010-2011 and 2016-2017, overall vaccine effectiveness was 49% for females and 38% for males, according to Danuta Skowronski, MD, MHSc, FRCPC, physician epidemiologist at the BC Centre for Disease Control and clinical professor in the school of population and public health at the University of British Columbia, and colleagues.
“As with other medical interventions, it has previously been assumed that males and females respond the same way to vaccination, but our findings question the validity of that assumption for influenza vaccine,” Skowronski told Infectious Disease News. “The effect of sex on influenza vaccine protection that we observed was not large, and our findings cannot be considered conclusive. They are best interpreted as a prompt for more definitive investigation of possible sex effects on influenza vaccine protection.”
According to the researchers, influenza vaccination coverage rates are higher among young adult women than young men in the United States and Canada. Additionally, they noted that many women work in health care and tend to be the primary caregiver for children and the elderly, increasing their likelihood of influenza exposure. Skowronski and colleagues investigated sex as a potential variable for the effectiveness of the influenza vaccine.
Influenza vaccination may be more effective in women than men, according to data from seven recent influenza seasons in Canada.
Source: Adobe Stock
They analyzed influenza vaccine effectiveness data from 2010-2011 to 2016-2017 from Canadian Sentinel Practitioner Surveillance Network (SPSN) databases. Sentinel practitioners collected respiratory samples from patients aged 1 year or older who presented within 7 days of influenza-like illness onset. Patients who tested positive for influenza by RT-PCR were included in the study, and patients who tested negative were added to the control group. Vaccination status, which was largely self-reported, was dependent upon patients receiving the seasonal influenza vaccine at least 2 weeks before symptom onset.
According to the study, 60% of the SPSN participants were female and 40% were male. This trend was observed among influenza cases and test-negative controls, Skowronski and colleagues said. However, 40% of females tested positive for influenza compared with 43% of males (P <.01). The higher vaccination coverage among females may account for why females were slightly less likely to test positive for influenza. Overall, 29% of females and 23% of males were vaccinated (P <.01). Similarly, 34% of female and 27% of male controls were vaccinated (P <.01).
Adjusted vaccination effectiveness varied by influenza subtype/lineage, age group and season, although effectiveness was higher among females compared with males, 49% (95% CI, 43%-55%) vs. 38% (95% CI, 28%-46% [absolute difference (AD) = 11%, P =.03]).
Age was also considered in the analysis, and the researchers observed the greatest difference in vaccine effectiveness between men and women among adults aged 50 years and older. In this group, adjusted vaccine effectiveness was 48% for women (95% CI, 38%-57%) compared with 29% for men (95% CI, 10%-44% [AD = 19%, P =.03]). In participants younger than age 20 years, vaccination effectiveness was closer between the sexes: 49% among females (95% CI, 31%-62%) and 45% among males (95% CI, 24%-59% [AD = 4%, P =.74]).
According to the study, the majority of SPSN participants were aged 20 to 49 years and vaccination effectiveness was slightly higher in men (48%; 95% CI, 33%-60%) than in women (47%; 95% CI, 37%-56% [AD = -1%, P =.90]).
Skowronski called the clinical implications of the findings “uncertain.” The researchers emphasized that more definitive research into the association between sex, age and vaccination effectiveness is needed.
“Ideally, sex differences would be explored through gold standard randomized controlled trial (RCT) design,” Skowronski said. “To begin, pre-existing RCT datasets could also be retrospectively explored for sex differences in influenza vaccine efficacy and if the signal we report is confirmed, future studies might include the collection of biological specimens to investigate potential underlying mechanisms (hormonal, immunological, genetic).” – by Marley Ghizzone
Disclosures: Skowronski is principal investigator on grants received from the Canadian Institutes of Health Research and the Public Health Agency of Canada in support of this work. Please see the study for all other authors’ relevant financial disclosures.